alea-institute/kl3m-data-sample-004-shuffled huggingface dataset:
<PAGE>   1
                                  UNITED STATES
                       SECURITIES AND EXCHANGE COMMISSION
                             WASHINGTON, D.C. 20549


                                    FORM 8-K
                                 CURRENT REPORT


                     PURSUANT TO SECTION 13 OR 15(d) OF THE
                         SECURITIES EXCHANGE ACT OF 1934

          DATE OF REPORT (DATE OF EARLIEST EVENT REPORTED) MAY 19, 1998

                               PENFORD CORPORATION
               --------------------------------------------------
               (EXACT NAME OF REGISTRANT AS SPECIFIED IN CHARTER)

                                   WASHINGTON
               ---------------------------------------------------
                 (STATE OR OTHER JURISDICTION OF INCORPORATION)

               0-11488                           91-1221360
      ------------------------        --------------------------------
      (COMMISSION FILE NUMBER)        (IRS EMPLOYER IDENTIFICATION NO.)

     777-108TH AVENUE N.E., SUITE 2390
          BELLEVUE, WASHINGTON                   98004-5193
     
----------------------------------------     --------------------
(ADDRESS OF PRINCIPAL EXECUTIVE OFFICES)          (ZIP CODE)


        REGISTRANT'S TELEPHONE NUMBER, INCLUDING AREA CODE (425) 462-6000
                                 ---------------


                        ---------------------------------
          (FORMER NAME OR FORMER ADDRESS, IF CHANGED SINCE LAST REPORT)


<PAGE>   2
ITEM 5. OTHER EVENTS

        On May 19, 1998, the Registrant issued a press release announcing that
        its Board of Directors has approved a plan to effect a tax-free spin-off
        to its shareholders of the Company's pharmaceuticals subsidiary, Penwest
        Pharmaceuticals Co. (PPC). The plan is subject to the satisfaction of
        certain conditions. The press release is filed as an exhibit to this
        report and is incorporated by reference herein.





ITEM 7. FINANCIAL STATEMENTS, PRO FORMA FINANCIAL INFORMATION AND EXHIBITS


(C) EXHIBITS

99.1    Press release dated May 19, 1998


<PAGE>   3
SIGNATURES:

Pursuant to the requirements of the Securities Exchange Act of 1934,the
registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.


                                PENFORD CORPORATION

       May 19, 1998             By /s/ Jeffrey T. Cook
       ------------             ----------------------

            Date                Jeffrey T. Cook
                                Vice President, Finance and
                                    Chief Financial Officer
§ 556.380 Melengestrol. ( a ) [Reserved]
( b ) *Tolerances.* The tolerance for melengestrol is: ( 1 ) *Cattle.* Fat: 25 ppb.
( 2 ) [Reserved]
( c ) *Related conditions of use.* See § 558.342 of this chapter.
Exhibit 31.2



I, Mary G. Merritt, certify that:



1. I have reviewed this annual report on Form 10-KSB of Preferred Voice, Inc.;



2. Based on my knowledge, this annual report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements
made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this annual report;



3. Based on my knowledge, the financial statements, and other financial information included in this annual report, fairly present in all material respects the financial
condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this annual report.



4. The registrants other certifying officers and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act
Rules 13a-14 and 15d-14) for the registrant and we have:



a. designed such
disclosure controls and procedures to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this annual
report is being prepared;



b. evaluated the effectiveness of the
registrants disclosure controls and procedures as of a date within 90 days prior to the filing date of this annual report (the Evaluation Date); and



c. presented in this annual report our conclusions about the effectiveness of the disclosure controls and procedures based on our evaluation
as of the Evaluation Date;



5. The registrants other certifying officers
and I have disclosed, based on our most recent evaluation, to the registrants auditors and the audit committee of the registrants board of directors (or persons performing the equivalent function):



a. all significant deficiencies in the design or operation of internal controls which could
adversely affect the registrants ability to record, process, summarize and report financial data and have identified for the registrants auditors any material weaknesses in internal controls; and



b. any fraud, whether or not material, that involves management or other employees who have a
significant role in the registrants internal controls; and



6. The
registrants other certifying officers and I have indicated in this annual report whether or not there were significant changes in internal controls or in other factors that could significantly affect internal controls subsequent to the date of
our most recent evaluation, including any corrective actions with regard to significant deficiencies and material weaknesses.



|                                                                     
|---------------------------------------------------------------------
|                                                                     
|/s/    MARY G. MERRITT                                               
|Mary G. Merritt Chief Financial Officer (Principal Financial Officer)



July 14, 2004
§ 520.1604 Oclacitinib. ( a ) *Specifications.* Each tablet or chewable tablet contains 3.6, 5.4, or 16 milligrams (mg) of oclacitinib as oclacitinib maleate.
( b ) *Sponsor.* See No. 054771 in § 510.600(c) of this chapter.
( c ) *Conditions of use* — ( 1 ) *Amount.* Administer orally 0.18 to 0.27 mg/per pound of body weight (0.4 to 0.6 mg/kg body weight) twice daily for up to 14 days; then administered once daily for maintenance therapy.
( 2 ) *Indications for use.* For control of pruritus associated with allergic dermatitis and control of atopic dermatitis in dogs at least 12 months of age.
( 3 ) *Limitations.* Federal law restricts this drug to use by or on the order of a licensed veterinarian.
[78 FR 42007, July 15, 2013, as amended at 88 FR 55563, Aug. 16, 2023]
---

Exhibit 13.A

CERTIFICATION PURSUANT TO18 U.S.C. SECTION 1350, 
    AS ADOPTED PURSUANT TOSECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 In connection with the Annual Report of Petaquilla Minerals Ltd. (the “Company”) on Form 20-F for the fiscal period ended May 31, 2012, as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, Joao Manuel, Chief Executive Officer of the Company, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that to the best of my knowledge: 1.
      The Report fully complies with the requirements of Section 13(a) or 15(d), as applicable, of the Securities Exchange Act of 1934, as amended; and2.
      The information contained in the Report fairly presents, in all materials respects, the financial condition and results of operations of the Company. /s/ Joao Manuel 
    Joao Manuel
    (Principal executive officer) Dated: September 11, 2012 The foregoing certification is being furnished solely to accompany the Report pursuant to 18 U.S.C § 1350, and is not being filed for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, and is not to be incorporated by reference into any filing of the Company, whether made before or after the date hereof, regardless of any general incorporation language in such filing.


---
**IN THE SUPREME COURT OF THE STATE OF MONTANA No. DA 22** 
**- 0424**  SHAWN FOWLER,

Plaintiff/Appellee, v. DEPARTMENT OF JUSTICE MONTANA HOGHWAY PATROL,

Defendant/Appellant. **ORDER ON UNOPPOSED MOTION FOR SECOND EXTENSION**

**OF TIME TO FILE RESPONSE BRIEF** Appeal from the Montana Sixth Judicial District Court, Park County

Cause No. DV 2019

- 40 The Honorable Judge Brenda Gilbert, Presiding Michael A. Kauffman Patricia Klanke DRAKE LAW FIRM, P.C. 111 N. Last Chance Gulch, Suite 3J He le na, MT 59601 Telephone: (406) 495

- 8080 michael@drakemt.com patricia@drakemt.com Attorneys for Appellant Karl Knuchel Webster Crist KARL KNUCHEL, P.C. 101 North E Street P.O. Pox 953 Livingston, MT 5 9047 Telephone: (406) 222

- 0135 karl@knuchelpc.com webster@knuchelpc.com Attorneys for Appelle e 06/12/2023

Case Number: DA 22-04242

UPON review of the Unopposed Motion for Second Extension of Time to File Response Brief by counsel for the Plaintiff/Appellee herein and good cause appearing therefor,

IT IS HEREBY ORDERED that the time to file Appellee’s Response Brief is extended to the 18 th of July, 2023.

DATED this ____ day of June, 202 3.

____________________________ JUSTICE OF THE SUPRME COURT OF MONTANA

cc: Karl Knuchel Webster Crist Michael Kauffman Patricia Klanke

Electronically signed by: Mike McGrath Chief Justice, Montana Supreme Court

June 12 2023
<PAGE>   1
 
                                                                   EXHIBIT 23.03
 
               CONSENT OF ERNST & YOUNG LLP, INDEPENDENT AUDITORS
 
     We consent to the reference to our firm under the caption "Experts" and to
the use of our report dated January 28, 1998 (except for Note 9, as to which the
date is February 28, 1998), with respect to the financial statements of
GenQuest, Inc. included in the Registration Statement on Form S-4 and related
Prospectus of Corixa Corporation for the registration of shares of its common
stock.
 
                                          ERNST & YOUNG LLP
 
Seattle, Washington
December 22, 1998
1

Nesky, Anthony

From: Rosencrantz, Ingrid

Sent: Tuesday, April 28, 2015 11:06 AM

To: Nesky, Anthony

Subject: FW: 40 CFR 192 proposed revision has been signed - request for meeting

Needs to go into the docket

From: Fettus, Geoffrey [mailto:gfettus@nrdc.org]  

Sent: Wednesday, February 18, 2015 2:39 PM

To: Peake, Tom; Larson, Lance

Cc: Rosencrantz, Ingrid; Nesky, Anthony; Cherepy, Andrea

Subject: 40 CFR 192 proposed revision has been signed ‐ request for meeting

Tom & Ingrid, 

Thanks so much for the heads up to both NRDC and industry in early January, it was very helpful in preparing 

for the work on the draft 40 CFR 192 this spring. 

Per your draft, Dr. Lance Larson (NRDC Science Fellow) and myself request an opportunity to meet with you 

and relevant staff on the draft ISL uranium recovery rule. We think there are some very good parts, but there are 

several areas where we have questions and would much appreciate the opportunity to explore the agency’s 

thinking. Except for Thursday (I am in NYC for work), next week is a great time for us to meet. Any chance we 

can set aside an hour to talk? We are happy to come see you or we can host – please let us know some 

convenient times. Thanks again, 

Geoff Fettus 

       

GEOFFREY H. FETTUS

Senior Attorney

NATURAL RESOURCES 

DEFENSE COUNCIL

1152 15TH STREET NW, SUITE 300 

WASHINGTON, DC 20005

T 202.289.2371

GFETTUS@NRDC.ORG            NRDC.ORG

           

Please save paper. 

Think before printing.

From: Peake, Tom [mailto:Peake.Tom@epa.gov] 

Sent: Tuesday, January 06, 2015 2:01 PM 

To: ksweeney@nma.org; Fettus, Geoffrey 

Cc: Rosencrantz, Ingrid; Nesky, Anthony; Cherepy, Andrea 

Subject: 40 CFR 192 proposed revision has been signed 
2

Hello,

I have news for you to start the new year.

On December 31, 2014, the U.S. Environmental Protection Agency’s Administrator, Gina McCarthy, signed a proposed

rule to strengthen the “Health and Environmental Protection Standards for Uranium and Thorium Mill Tailings,” (40

Code of Federal Regulations Part 192 or 40 CFR 192) by adding new ground water protection standards for in‐situ

recovery (ISR) of uranium. The proposed standards apply to byproduct materials produced by uranium ISR, which has

overtaken conventional mining and milling as the dominant form of uranium recovery in the United States. The

standards proposed would be implemented by the U.S. Nuclear Regulatory Commission, once finalized.  

Attached are a pre‐publication version of the proposed rule and a fact sheet summarizing the proposal. The proposed

rule will be published in the Federal Register in the next few days, which will start a 90‐day public comment period. We

look forward to receiving your input.

If you have questions, please feel free to contact Ingrid Rosencrantz of my staff at rosencrantz.ingrid@epa.gov, phone

202‐343‐9286 or me at peake.tom@epa.gov or 202‐343‐9765.

Also, if you are on our list serv email list, you will get another notification, but I wanted to let you now given your

interest.

Happy New Year!

Tom Peake

US EPA Radiation Protection Division

Director, Center for Waste Management and Regulations

phone: 202‐343‐9765
#### § 336.3 Definition.

As used in this part:

*Antiemetic.* An agent that prevents or treats nausea and vomiting.
§ 582.5991 Zinc oxide. ( a ) *Product.* Zinc oxide.
( b ) *Conditions of use.* This substance is generally recognized as safe when used in accordance with good manufacturing or feeding practice.
|   | (1) | The Report fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934; and |
|--------|-----|-----------------------------------------------------------------------------------------------------------------------|

|   | (2) | The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company. |
|--------|-----|------------------------------------------------------------------------------------------------------------------------------------------------------|

|   | /s/Rick Etskovitz                                              |
|--------|----------------------------------------------------------------|
|   | Rick Etskovitz                                                 |
|   | Chief Financial Officer                                        |
|   | (Principal Financial Officer and Principal Accounting Officer) |
|   | June 7, 2013                                                   |
|   |                                                           |

----
Editorial Note on Part 73
Editorial Note: Nomenclature changes to part 73 appear at 66 FR 66742, Dec. 27, 2001.

§ 73.2725 Ultramarines. ( a ) *Identity.* The color additives, ultramarines (blue, green, pink, red, and violet) are pigments obtained by calcining at temperatures above 700 °C. a mixture of kaolin, sulfur, sodium carbonate, silicious matter, sodium sulfate, and carbonaceous matter, but not necessarily all these substances, to produce a single color. The ultramarines are complex sodium aluminum sulfosilicates having a typical formula Na(AlSiO)S with proportions of each element varying with each color.
( b ) *Specifications.* The ultramarines shall conform to the following specifications and shall be free from impurities other than those named, to the extent that such other impurities may be avoided by good manufacturing practice. Lead (as Pb), not more than 20 parts per million. Arsenic (as As), not more than 3 parts per million. Mercury (as Hg), not more than 1 part per million.
( c ) *Uses and restrictions.* The ultramarine pigments may be safely used for coloring externally applied cosmetics, including cosmetics intended for use in the area of the eye, in amounts consistent with good manufacturing practice.
( d ) *Labeling requirements.* The color additives and any mixtures prepared therefrom intended solely or in part for coloring purposes shall bear, in addition to any other information required by law, labeling in accordance with § 70.25 of this chapter.
( e ) *Exemption from certification.* Certification of this color additive is not necessary for the protection of the public health, and therefore batches thereof are exempt from certification pursuant to section 721(c) of the act.
- All
            - Title
            - Author
            - Subject
            - Date
            - Full-Text

            -                              Explore                            ******                - Educational Resources
              - Archival Collections
              -                                      Themes                                    ******                  - Economic Data
                - Federal Reserve
                - View all 
              - Timelines 
            -                              Browse                            ******                - Titles
              - Authors
              - Subjects
              - Dates 
            -                              About                            ******                - About FRASER
              - FAQ
              - Contact Us
              -                                      FRASER API                                    ******                  - REST API
                - OAI-PMH 
            - Inside FRASER Blog

            - **

Home                 > Browse by Title > Fair Labor Standards Act of 1938

              														Fair Labor Standards Act of 1938, June 25, 1938.						https://fraser.stlouisfed.org/title/5567,			accessed on September 5, 2024.						    

        - **FRASER**
        - About
        - FAQ
        - Legal and Privacy
        - FRASER API

          -                              @FedFRASER 
          - ** Contact Us
          -  **  What's New  
          -  **  Inside FRASER
# C_2015007EN.01006101.xml

| 12.1.2015 | EN | Official Journal of the European Union | C 7/61 |
| --- | --- | --- | --- |

12.1.2015

EN

Official Journal of the European Union

C 7/61

---

Action brought on 3 November 2014 — ZZ v EEAS

(Case F-129/14)

(2015/C 007/79)

Language of the case: French

Parties

Parties

Applicant: ZZ (represented by: J.-N. Louis, R. Metz, D. Verbeke, lawyers)

Applicant:

Defendant: EEAS

Defendant:

Subject-matter and description of the proceedings

Subject-matter and description of the proceedings

The annulment of the EEAS’ decision to remove the applicant from his post without reducing his pension rights.

Form of order sought

Form of order sought

| — | Annul the EEAS’ decision of 16 January 2014 to remove the applicant from his post without reducing his pension rights; |
| --- | --- |

—

Annul the EEAS’ decision of 16 January 2014 to remove the applicant from his post without reducing his pension rights;

| — | Order the EEAS to pay the costs. |
| --- | --- |

—

Order the EEAS to pay the costs.

---
§ 522.380 Chloral hydrate, pentobarbital, and magnesium sulfate. ( a ) *Specifications.* Each milliliter of solution contains 42.5 milligrams (mg) of chloral hydrate, 8.86 mg of pentobarbital, and 21.2 mg of magnesium sulfate.
( b ) *Sponsor.* See No. 054771 in § 510.600(c) of this chapter.
( c ) *Conditions of use* — ( 1 ) *Amount.* For general anesthesia: Administer 20 to 50 milliliters per 100 pounds of body weight by intravenous injection until the desired effect is produced. Cattle usually require a lower dosage on the basis of body weight. As a sedative-relaxant: Administer at a level of one-fourth to one-half of the anesthetic dosage level.
( 2 ) *Indications for use.* For general anesthesia and as a sedative-relaxant in cattle and horses.
( 3 ) *Limitations.* Federal law restricts this drug to use by or on the order of a licensed veterinarian.
[79 FR 16185, Mar. 25, 2014]
<TABLE> <S> <C>

<ARTICLE> 5
<LEGEND>
THIS SCHEDULE CONTAINS SUMMARY FINANCIAL INFORMATION EXTRACTED FROM THE
SEPTEMBER 30, 1995 FORM 10Q AND IS QUALIFIED IN ITS ENTIRETY BY REFERENCE TO
SUCH FINANCIAL STATEMENTS.
</LEGEND>
<MULTIPLIER> 1,000
<CURRENCY> U.S.DOLLARS
       
<S>                             <C>
<PERIOD-TYPE>                   9-MOS
<FISCAL-YEAR-END>                          DEC-31-1995
<PERIOD-START>                             JAN-01-1995
<PERIOD-END>                               SEP-30-1995
<EXCHANGE-RATE>                                      1
<CASH>                                           4,742
<SECURITIES>                                     1,935
<RECEIVABLES>                                   15,764
<ALLOWANCES>                                       974
<INVENTORY>                                      7,307
<CURRENT-ASSETS>                                32,521
<PP&E>                                          13,885
<DEPRECIATION>                                   7,057
<TOTAL-ASSETS>                                  49,389
<CURRENT-LIABILITIES>                           13,146
<BONDS>                                          1,101
<COMMON>                                           169
<PREFERRED-MANDATORY>                                0
<PREFERRED>                                          0
<OTHER-SE>                                      34,973
<TOTAL-LIABILITY-AND-EQUITY>                    49,389
<SALES>                                              0
<TOTAL-REVENUES>                                30,175
<CGS>                                                0
<TOTAL-COSTS>                                   19,510
<OTHER-EXPENSES>                                14,151
<LOSS-PROVISION>                                     0
<INTEREST-EXPENSE>                                 212
<INCOME-PRETAX>                                  3,698
<INCOME-TAX>                                         0
<INCOME-CONTINUING>                              3,698
<DISCONTINUED>                                       0
<EXTRAORDINARY>                                      0
<CHANGES>                                            0
<NET-INCOME>                                     3,698
<EPS-PRIMARY>                                      .22
<EPS-DILUTED>                                      .22
        

</TABLE>
#### § 70.20 Packaging requirements for straight colors (other than hair dyes).

Straight colors shall be packaged in containers which prevent changes in composition. Packages shall be sealed so that they cannot be opened without breaking the seal. An unavoidable change in moisture content caused by the ordinary and customary exposure that occurs in good storage, packing, and distribution practice is not considered a change in composition. If the packaging material is a food additive it shall be authorized by an appropriate regulation in parts 170 through 189 of this chapter.
#### § 640.10 Red Blood Cells.

The proper name of this product shall be Red Blood Cells. The product is defined as red blood cells remaining after separating plasma from human blood.

[38 FR 32089, Nov. 20, 1973, as amended at 50 FR 4138, Jan. 29, 1985]